$LLY

Recent Trump mentions

• News7d ago

  ‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadership in anti-obesity drugs through ongoing innovation and development. With successful trials for drugs like retatrutide an… On the back of a global boom in anti-obesity drugs and its blockbuster formulations such as Mounjaro, Eli Lilly has seen its market capitalisation surge five times in six years, and is now the only p… [+10700 chars]

  $LLY

  Source ↗
• News13d ago

  Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market. The Eli Lilly and Novo Nordisk logos. Every time Novo urges investors to look ahead, Eli Lilly gives them another reason to look back at its widening lead over the Danish drugmaker.  Novo this week… [+10000 chars]

  $LLY

  Source ↗
• News16d ago

  Twist Bioscience (TWST) Expands AI Drug Discovery Exposure With Lilly TuneLab Partnership Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug di... Twist Bioscience Corporation (NASDAQ:TWST) is on the cusp of gaining significant exposure to the rapidly evolving artificial intelligence (AI)-driven drug discovery ecosystem. On September 16, the co… [+4994 chars]

  $LLY

  Source ↗
• News17d ago

  Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space. Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo, as the company tries to catch up to a lead in the space established by riva… [+2386 chars]

  $LLY

  Source ↗
• News21d ago

  A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NA... On September 8, 2026, CNBC reported that Novartis' failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE… [+5428 chars]

  $LLY

  Source ↗
• News21d ago

  Eli Lilly (LLY) Gets a Big Price Target Boost, Analysts See 20% Upside On September 15, Berenberg upgraded its rating on Eli Lilly and Company (NYSE:LLY) from Hold to Buy and lifted its price target from $1,220 to $1,400. The re... On September 15, Berenberg upgraded its rating on Eli Lilly and Company (NYSE:LLY) from Hold to Buy and lifted its price target from $1,220 to $1,400. The research firm pointed to the company's stro… [+3746 chars]

  $LLY

  Source ↗
• News21d ago

  Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight,... On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 weight-loss drugs still lose weight, though far less than at full recommended d… [+5142 chars]

  $LLY

  Source ↗
• News23d ago

  Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss... Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against N… [+6260 chars]

  $LLY

  Source ↗
• News23d ago

  From Novo Nordisk to ‘Novo’: A Strategic Reset Amid Rising Lilly Pressure Novo Nordisk A/S (NYSE:NVO)’s decision to rebrand its day-to-day identity as “Novo” and launch a cultural reset is primarily a strategic response to the comp... Novo Nordisk A/S (NYSE:NVO)'s decision to rebrand its day-to-day identity as "Novo" and launch a cultural reset is primarily a strategic response to the company's loss of momentum in the obesity-drug… [+5386 chars]

  $LLY

  Source ↗
• News26d ago

  Eli Lilly’s (LLY) GLP-1 Growth Made It a Core “Running Back” Stock for Jim Cramer During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP... During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Co… [+4006 chars]

  $LLY

  Source ↗
• News9/5/2026

  Lilly Launches Foundayo in the UK as NICE Review Continues Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company’s oral treatment fo... Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company's oral treatment for weight management and type 2 diabetes is… [+4854 chars]

  $LLY

  Source ↗
• News8/31/2026

  Eli Lilly (LLY) Makes a $2.88 Billion Autoimmune Bet. What Could Go Right or Wrong? Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and m... Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based payments. The deal is expec… [+5111 chars]

  $LLY

  Source ↗
• News8/28/2026

  Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI? On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop... On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveragin… [+4889 chars]

  $LLY

  Source ↗
• News8/21/2026

  Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it wi... Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant… [+3898 chars]

  $LLY

  Source ↗
• News8/16/2026

  Eli Lilly’s (LLY) Growth Story Keeps Adding Chapters On August 5, Eli Lilly (NYSE:LLY) told investors its second quarter delivered 48% revenue growth, and the days since have brought even more good news. A UK r... On August 5, Eli Lilly (NYSE:LLY) told investors its second quarter delivered 48% revenue growth, and the days since have brought even more good news. A UK regulatory approval, a new Medicare access … [+4238 chars]

  $LLY

  Source ↗
• News8/15/2026

  Eli Lilly’s Weight-Loss Pill Just Got Its First Foothold in Europe Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain’s drug regulator authorized the company’s oral GLP-1 drug orf... Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain's drug regulator authorized the company's oral GLP-1 drug orforglipron, becoming the first country in E… [+4221 chars]

  $LLY

  Source ↗
• News8/15/2026

  Can Veeva Systems Inc. (VEEV)’s AI Platform Keep Pace With Eli Lilly and Company (LLY)’s Explosive Growth On August 11, Veeva Systems Inc. (NYSE:VEEV) announced that Eli Lilly and Company (NYSE:LLY) committed to deploying Veeva Vault CRM globally. Vault CRM serve... On August 11, Veeva Systems Inc. (NYSE:VEEV) announced that Eli Lilly and Company (NYSE:LLY) committed to deploying Veeva Vault CRM globally. Vault CRM serves as the core infrastructure for "agentic … [+4457 chars]

  $LLY

  Source ↗
• News8/11/2026

  Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market? The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO... The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court i… [+6998 chars]

  $LLY

  Source ↗
• News8/10/2026neutral

  Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies? For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But... For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conv… [+7312 chars]

  $LLY

  Source ↗
• News8/10/2026neutral

  Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat? The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years com... The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, … [+8465 chars]

  $LLY

  Source ↗
• News8/9/2026neutral

  Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of... Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier,… [+4101 chars]

  $LLY

  Source ↗
• News8/5/2026neutral

  Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth In this week’s edition of InnovationRx, we look at Lilly’s 2Q earnings, a cannabis-derived drug for PTSD, Apnimed’s IPO and more In this weeks edition of InnovationRx, we look at Lillys 2Q earnings, a cannabis-derived drug for PTSD, Apnimeds IPO and more. To get it in your inbox, subscribe here. Eli Lilly CEO David Ricks Get… [+3037 chars]

  $LLY

  Source ↗
• News8/4/2026positive

  'Godzilla' weight-loss shot that's more powerful than Ozempic set to be offered to some patients ahead of FDA approval: Find out if you're eligible Eli Lilly announced Monday a limited number of patients can apply for early access to the weight-loss shot retatrutide, ahead of FDA approval. Obese patients who struggle to slim down on today's blockbuster weight-loss shots are set to be offered retatrutide, an experimental drug that helped patients lose up to a quarter of their body weigh… [+4176 chars]

  $LLY

  Source ↗
• News8/4/2026neutral

  Is Eli Lilly (LLY) Still the Undisputed Leader in the $150 Billion Obesity Drug Market? Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to... Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund".A copy of the letter is available todownload here. The Fund gained 11.99% during… [+3958 chars]

  $LLY

  Source ↗
• News8/3/2026neutral

  GLP-1 battle heats up again as Novo claws its way back into race with Lilly The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financia… [+5211 chars]

  $LLY

  Source ↗

Disclosed trades

No disclosed trades for $LLY.